• Contact Us
  • About
  • Advertise
  • Careers
Kashmir Dot Com
  • Home
  • Kashmir
  • Jammu
  • World
  • Politics
  • Opinion
  • Business
  • Health
  • Contact Us
No Result
View All Result
  • Home
  • Kashmir
  • Jammu
  • World
  • Politics
  • Opinion
  • Business
  • Health
  • Contact Us
No Result
View All Result
Kashmir Dot Com
No Result
View All Result
Home Health

Influenza drug Molnupiravir reduces risk of death in Covid patients: DAK

‘Drug effective against Omicron’

Kashmir Dot Com by Kashmir Dot Com
December 29, 2021
in Health
0
DAK President Dr Nisar ul H

DAK President Dr Nisar ul H

0
SHARES
29
VIEWS
Share on Facebook

Srinagar, Dec 29: With the approval of influenza drug Molnupiravir for Covid-19 patients, Doctors Association Kashmir (DAK) on Wednesday said the drug reduces the risk of hospitalization and death in Covid patients.

“Molnupiravir prevents death in Covid patients when given early in the course of illness,” said DAK President and Influenza expert Dr Nisar ul Hassan.

Quoting a study, Dr Hassan said Molnupiravir reduced the risk of hospitalization and death from Covid by 30 percent.

“The drug was found to have life-saving benefits in mild to moderate cases of Covid-19 who were at risk of developing severe disease,” he said.

“The study also reported that Molnupiravir was equally effective against the Gamma, Delta and Mu variants as it was against the original strain,” he added.

The DAK President said while the drug was not tested against Omicron, early data suggests that the drug is effective against the new variant.

“Originally developed to treat influenza, Molnupiravir is a repurposed oral antiviral drug that works by blocking the virus from replicating in the body,” he said.

Dr Nisar said the drug can safely be given to adults above 18 years of age.

“The drug is not recommended for use in children and pregnant women. It is not to be used for prevention of Covid or in patients hospitalized due to Covid,” he said.

“However, if it was initiated before hospitalization, it may be continued,” he added.

General Secretary DAK Dr Arshad Ali said Molnupiravir can be taken twice a day for five days by people at home.

“The pill has to be started as soon as possible, within five days of the start of symptoms,” he said.

“With the winter surge of Covid cases and the arrival of Omicron variant, the drug could provide a much needed arsenal to prevent Covid infection from culminating in severe disease,” he added.

Spokesperson DAK Dr Riyaz Ahmad Dagga said the antiviral drug has received approval in several countries like US and UK.

“Yesterday, India’s drug regulatory body cleared molnupiravir for the treatment of adult Covid-19 patients with mild to moderate disease and who have at least one risk factor for poor disease outcome,” he said.

“The risk factors that can put Covid patients at risk of severe disease include obesity, old age or underlying medical conditions like diabetes, heart, lung, kidney or liver disease, and cancer,” he added. (KDC)

Previous Post

Hyderpora probe; A fig leaf to legitimise violence by state: Peoples Conference

Next Post

Court convicts 2 persons for cheating on pretext of providing MBBS seat

Next Post

Court convicts 2 persons for cheating on pretext of providing MBBS seat

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

ADVERTISEMENT

LATEST NEWS

Amid Freezing Temperatures, Ladakh Begins Panchayat, Municipal Polling

Night Temperatures Rise Sharply Across J&K, Remain Above Normal at Most Stations

Pakistani National Apprehended by BSF Along IB in J&K

J&K Wins Prestigious India Sports Award For “Excellence In Promoting Sports”

FDA Intensifies Food Safety Drive in J&K; Conducts 157 Inspections, Lifts 53 Samples

Chief Justice visits District Court Complex Budgam; emphasizes collective efforts to strengthen Justice System, cautious use of AI

GOC Northern Command reviews counter infiltration measures along LoC in Poonch, Sunderbani sectors

No Compromise in Delivery of Essential Public Services: DC Baramulla Directs Officers at Block Diwas

Kashmir Police Holds Third Conference on Citizen-Centric Beat Policing, Stresses SMART Policing

Dismantle Entire Terror-Separatist Ecosystem: LG Sinha to Police Officials

Facebook Twitter

About Us

Kashmir Dot Com (KDC) is J&K's premier News Agency having a vast reach of audience.

Kashmir Dot Com is a News Agency based in Srinagar, J&K that offers syndicated multimedia news feed to plethora of news-bureaus in J&K and beyond. We also provide a range of facilities from foreign and domestic channels to package their reports in Jammu and Kashmir. We cover almost all areas of interest in J&K to viewers including news, entertainment, and life styles, bussiness, sports, human-interest features and social and developmental issues.

KDC can well and truly take pride in the legacy of it's work, and in it's contribution towards the building of a free and fair Press in Jammu and Kashmir.

Category

  • Business
  • Entertainment
  • Health
  • JAMMU
  • Kashmir
  • Lead
  • National
  • Opinion
  • Politics
  • Science
  • Sports
  • Tech
  • Uncategorized
  • World

Company Info

  • Contact Us
  • About
  • Advertise
  • Careers

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.

error: Content is protected !!
No Result
View All Result
  • Home
  • Kashmir
  • Jammu
  • World
  • Politics
  • Opinion
  • Business
  • Health
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.